Introduction
============

Gastric cancer is one of the leading deadly malignancies in both sexes worldwide, especially in eastern Asia ([@B39]). In 2017, it is estimated the number of stomach cancer deaths in China will reach 2.21 million, ranking third in the world and second in China ([@B4]; [@B7]). Recent epidemiologic studies have found that patients with diabetes have a higher risk of gastric cancer, and the long-term use of metformin is associated with a lower risk of gastric cancer compared with the lack of use of metformin ([@B40]; [@B29]). It is believed that the occurrence of gastric cancer is related to energy metabolism, blocking these metabolic alterations is now emerging as a new therapeutic approach of cancer, and some of metabolic enzymes involved in the glycolytic pathway are currently considered as new therapeutic targets ([@B37]).

Hepatocyte nuclear factor 4α (HNF4α) is a nuclear transcription factor that binds DNA as a homodimer ([@B20]). Multiple HNF4α isoforms exist in humans and are suggested to have different physiological roles in development and transcriptional regulation of target genes. Previous studies have found that HNF4α is a key regulator of a number of genes involved in glucose, cholesterol and fatty acid metabolism, and HNF4α mutations cause monogenic type 2 diabetes of the young ([@B35]; [@B30]). Recent studies have shown that changes in HNF4α gene expression are associated with many types of cancers, such as hepatocellular carcinoma, renal cell carcinoma, gastric adenocarcinoma, small intestine carcinoma, and colorectal cancer ([@B11]). Moreover, many studies have found that HNF4α is highly expressed in gastric cancer tissues, especially in Asia ([@B6]; [@B31]). The expression of HNF4α is seen in primary gastric adenocarcinomas and in metastases of gastric carcinoma to the breast, but is absent in primary breast carcinomas, and in metastases of breast carcinomas to the stomach ([@B42]). What's the molecular mechanism of HNF4α, a nuclear receptor that activates the expression of genes involved in glucose, fatty acid and cholesterol metabolism, in the development of gastric cancer?

Berberine (BBR) is a natural isoquinoline alkaloid extracted from plants, such as berberis aquifolium, vulgaris, aristata, and tinospora cordifolia ([@B38]). BBR was used to be an antibacterial agent in China for a long time. Over the past decade, It has been reported that BBR could also regulate plasma lipid and glucose levels in type 2 diabetes animal models and humans ([@B24]; [@B34]; [@B38]; [@B43]). Our previous studies have also indicated that BBR can stimulate insulin secretion and modulate lipids in impaired glucose tolerance rats ([@B27]), reverse free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes ([@B55]), even attenuate intestinal mucosal barrier dysfunction and immune barrier damages in type 2 diabetic rats ([@B16]). And the molecular mechanism which BBR modulates lipid metabolism, inhibits hepatic gluconeogenesis and enhances insulin secretion is targeting HNF4α ([@B46]; [@B47]). Recent studies revealed that BBR can inhibit the growth of gastric tumor, the anti-cancer effect of BBR is through inhibiting glucose uptake and reducing the transcription of glucose metabolism relative genes ([@B44]; [@B32]). So does Berberine share same molecular target in metabolism regulation and in anti-tumor developing?

In the present study, firstly, we investigated the anti-gastric cancer effect of BBR on GC cell lines. Secondly, the lentivirus infection was used to silence HNF4α in SGC7901 cell to demonstrate whether HNF4α was a key target for anti-gastric cancer. Then, BI6015 (an HNF4α antagonist), AICAR (an AMPK activator), Compound C (AMPK-kinase inhibitor), metformin and LV-HNF4α-RNAi SGC7901 cell model was used to detect the molecular mechanism of BBR in GC cell lines. Finally, we used SGC7901 and LV-HNF4α-RNAi SGC7901 mouse-xenograft models to demonstrate the effect of BBR and HNF4α *in vivo*. Our results revealed that Berberine, a metabolism-regulated drug, could inhibit GC cells proliferation, migration and invasion and suppress GC tumor growth. The anti-gastric cancer mechanism of BBR might be involved in AMPK- HNF4α-WNT5A signaling pathway and HNF4α is a key molecule target.

Materials and Methods {#s1}
=====================

Materials
---------

Berberine chloride (BBR), dimethyl sulfoxide (DMSO) and Compound C were obtained from Sigma-Aldrich, United States. BI6015 (an HNF4α antagonist) and AICAR (AMPK activator) were provided by the TOCRIS Bio-Techne. Metformin was purchased from Tongji Hospital. Cultrex PathClear Basement Membrane Extract (BME) was obtained from RDsystems. Mouse monoclonal Antibodies against human AMPK, p-AMPK, HNF4α, β-catenin, E-cadherin, cyclin D1, MMP-3, and C-myc were obtained from Cell Signaling Technologies (Boston, MA, United States), WNT5A was purchased from Abgent. Another Antibody against HNF4α (sc-374229) was obtained from Santa Cru Biotechnology (Santa Cruz, CA, United States), which was used for immunohistochemistry of mouse tumor tissue.

Cell Culture
------------

Hubei Biossci Biological Co., Ltd., supported the GC cell lines SGC7901 and AGS. The SGC7901 and AGS cells were cultured in RPMI 1640 medium (HyClone, China) with 10% fetal bovine serum (FBS) (SiJiQing, China), 1% penicillin-streptomycin-amphotericin solution at 37°C in a humidified chamber with 5% CO~2~. When cells were in logarithmic growth phase, they were given drug treatment.

Small Interfering RNA Transfection
----------------------------------

Lentiviruses which carried the small interfering human HNF4α RNA (siRNA) were purchased from Gikai Gene and used to transfect cell to silence the expression of HNF4α. Lentiviruses without the siRNA gene were generated as a control and designated as Lenti-GFP. The transfection medium was removed after 12 h, replaced with fresh medium, and the cells then grown in 5% CO~2~ at 37°C for an additional 48--72 h. Stably transfected cells were selected by puromycin. RT-PCR and western blot analyses were performed to confirm target knockdown by siRNA.

MTT Assay
---------

Cell growth was assessed with a standard 3-(4,5-dimethyl-2-tetrazolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay. A total of 5 × 10^3^ cells were seeded in each well of 96-well culture plates. After 8 h, the cells were treated with different concentrations of drugs (Berberine 10∼80 μM, metformin 10∼80 mM). After 24, 48, and 72 h, the culture medium was removed, and 20 μl of a 0.5 mg/ml solution of MTT (Sigma-Aldrich) was added to each well. The plates were then incubated for 4 h at 37°C. The MTT solution was then removed and replaced with 100 μl of DMSO (Wuhan Goodbio Technology Co., Ltd.) per well, and the absorbance at 570 nm was measured using an Enzyme-linked immunoassay (Synergr2 BioTek, United States).

Migration and Invasion Assays
-----------------------------

Cells were trypsinized and resuspended in serum-free medium at a concentration of 1 × 10^5^ cells/ml. Approximate 2 × 10^4^ cells were seeded in the upper chamber (Millipore, United States) seated on 24-well plate, and 750 μl complete medium with 10% FBS was added to each well of the plate as the lower chamber. After 16 h of incubation, non-filtered cells were removed using a cotton swab. Migratory cells on the underside of membrane were fixed and stained with 0.1% crystal in five different fields at 200× magnification.

Cell invasion was examined using Corning chamber assays. The bottom of the Transwell membrane was pretreated with 100 μl Cultrex PathClear Basement Membrane Extract (RDsystems) for 2 h at 37°C. Afterward, 5 × 10^4^ cells re-suspended in serum-free 1640 were plated in the upper chamber of a trans-well apparatus (8.0 um pore, Corning), while 750 μl of 1640 with 10% FBS were provided in the lower chamber. After incubation at 37°C for 24 h, cells that migrated to the bottom of the membrane were attached and fixed, stained with 0.5% crystal violet, and cells in the upper chamber were removed with a cotton sticker. The images were acquired using a light microscope. The cells were examined under a fluorescence microscope. (×200, Nikon).

Cell Cycle Analysis by Flow Cytometry
-------------------------------------

Cell cycle distribution assay by flow cytometry. Cell cycle analysis was determined by PI staining. Briefly, AGS and SGC7901 cells were treated with drugs for 48 h, and then were blended with 13-methyl-palmatrubine. Treated and control cells were harvested, washed twice with phosphate buffered saline (PBS) and fixed with pre-cooled 70% ethanol for 24 h at 4°C. Fixed cells were washed, pelleted, re-suspended in 500 μl PBS containing 50 μg RNase A at 37°C and then stained with 5 μg PI in the dark at room temperature for 30 min. Finally, cell cycle distributions were immediately assessed using a FACSort Flow Cytometer (BD Biosciences, San Jose, CA, United States).

Western Blot Analysis
---------------------

Cells were washed twice with cold PBS and then were suspended in 100 μl RIPA lysis buffer for 30 min at 4°C, vortexed every 10 min, and then centrifuged at 12000 ×*g* for 15 min. The supernatants containing the total protein extracts were collected. Protein concentration was measured by the BCA. Sample proteins (60 μg of protein/lane) on a 10% SDS-polyacrylamide electrophoresis gel (SDS--PAGE).The electrophoresis was carried out first at 80 V for 30 min and followed by 120 V for 60 min. The proteins were separated using SDS--PAGE gel and transferred onto NC membranes (0.4 um, Millipore, United States). The transferred NC membranes were incubated for 1 h with 5% non-fat milk blocking buffer, the primary antibody (1:800 or 1:1000) were incubated overnight with gentle agitation at 4°C. The membranes were washed three times and incubated with the second antibody (1:8000 or 1:10000) at room temperature for 1 h and subsequently were visualized with a near-infrared double color laser imaging system (Odyssey, Lincoln, NE, United States).

RNA Isolation and Quantitative PCR Analyses
-------------------------------------------

Total RNA was extracted from cultured cells in the exponential phase of growth using the TRIzol Reagent (Magen, Wuhan) according to the manufacturer's instructions. cDNA was synthesized from 2 μg of total RNA using the 5X All-In-One RT MasterMix (abm) at 42°C for 15 min and at 85°C for 5 min. Real-time PCR reactions were performed using EvaGreen 2X qPCR MasterMix at 95°C for 10 min, 95°C for 15 s and 60°C for 60 s, 40 cycles. Relative quantity of HNF4α, WNT5A, C-myc, CyclinD1, β-catenin, MMP-3 and E-cadherin were calculated using the ΔΔCt method with GAPDH as reference control. The reproducibility of the measurements was assessed by performing triplicate reactions. The primer sequences are listed in **Table [1](#T1){ref-type="table"}**.

###### 

Primers for RT-PCR assay.

  Gene         Forward (5′-3′)           Reverse (5′-3′)
  ------------ ------------------------- --------------------------
  AMPKα 2      CAATCGTTCTGTCGCCACTC      TCTTTCACAGCCTCATC ATCAA
  HNF4α        TGGTGGACAAAGACAAG AGGAA   GAGCGCATTGATGGAGGG
  WNT5a        CGACTATGGCTACCGCTTTG      AGGGCATCACCCACCTTG
  β-catenin    TGCTGAAGGTGCTATCT GTCTG   CCTTCCATCCCTTCC TGTTT
  CyclinDl     GTGACCACCACCCCAACAA       CCTTTCCCGACCCTGCTA
  E-cadherin   CCGCCGGCGTCTGTAGGAA       AGGGCTCTTTGACCACCG CTCTC
  MMP-3        GGCCTGGAACAGTCTTGGC       TGTCCATCGTTCATCAT CGTCA
  C-MYC        GGATTCTCTGCTCTCC TCGAC    CTCCAGCAGAAGGTG ATCCA
  GAPDH        AATCCCATCACCATCT TCCAG    GAGCCCCAGCCTTC TCCAT

Xenograft Model Analysis
------------------------

Animal experiments were carried out according to the institutional guidelines and regulations. All animal studies were approved by the Huazhong University of Science and Technology Institutional Animal Care and Use Committee (S787). We purchased 18 female athymic mice (BALB/c-nude; 4 weeks old; 13--16 g) from Hunan Slake Jingda Experimental Co., Ltd. (Hunan, China). The animals were maintained under specific pathogen-free condition using a laminar airflow rack and had continuous free access to sterilized flood and autoclaved water. Nine mice were inoculated with SGC7901 cells (10^7^ cells per animal) subcutaneously on the right flank regions of the mouse. The rest 9 mice were inoculated with normal control (*n* = 3), Lenti-GFP (*n* = 3), and LV-HNF4α-RNAi (*n* = 3) SGC7901 cells (10^7^ cells per animal), respectively, subcutaneously on the right flank regions of the mouse. Seventy-two hours later, the xenografts were identifiable as a mass of more than 6 mm in maximal diameter in all recipients. The SGC7901 mouse-xenograft models were randomly assigned to three groups (control group, *n* = 3; BBR group, *n* = 3; and MET group, *n* = 3). Mice were gavaged with PBS alone (control), BBR (100 mg/kg/day), MET (250 mg/kg/day) every other day starting on day 3. Tumor volume was calculated every third day as follows: tumor volume (mm^3^) = \[tumor length (mm) × tumor width (mm)^2^\]/2. All animals were sacrificed on day 18 after treatment. All animals were alive during the observation.

Immunohistochemistry Staining
-----------------------------

Solid tumors were removed from sacrificed mice and fixed with 4% formaldehyde. Paraffin-embedded tumors tissue were sliced on 4-μm thick and mounted on APES-coated slides. Slides were deparaffinized in xylene and rehydrated in graded ethanol. Endogenous peroxidase activity was quenched with a 3% hydrogen peroxide solution in methanol at room temperature for 30 min, followed by rinsing in pH 6.0 PBS. After antigen retrieval in a water bash set in a 10 mmol/L citrate buffer (pH 6.0) at 94°C for 8 and 10 min, respectively, the slides were immediately cooled for 20 min at room temperature, Non-specific binding sites were blocked by incubation with wash buffer containing 10% normal goat serum at 37°C for 30 min. The sections were then incubated overnight at 4°C with a primary antibodies against HNF4α (at 1:100; Santa Cruz), WNT5A (at 1:80; abs113167 Abgent), and β-catenin (at 1:100; Cell Signaling Technologies). The positive stains were shown as brown color by peroxidase substrate solution DAB, and samples were lightly counterstained with hematoxylin. Specimens were examined under a light microscope.

Statistical Analysis
--------------------

All data were analyzed by Graph Pad Prism 6 software and expressed as the mean ± SD. Significance among groups was analyzed by one-way analysis of variance (ANOVA), followed by Dunnett's multiple comparison post-test. A value with P \< 0.05 was considered significant.

Results
=======

Effect of Berberine on Cell Proliferation in GC Cells
-----------------------------------------------------

To address the effect of BBR on gastric cancer cells growth, we evaluated GC cell viability using MTT assay. As shown in **Figure [1A](#F1){ref-type="fig"}**, treatment with increasing concentration of BBR (10--80 μM) resulted in growth inhibition of AGS and SGC7901 cells, also in a time-dependent manner (24, 48, and 72 h), although BBR had an unstable inhibitory effect on SGC7901 cells at 24 h (40--60 μM). Metformin (MET, 10--80 mM) was chosen as positive control ([@B6]). The result showed that MET had same proliferation inhibition effect on AGS and SGC7901, with a time- and dose-dependent manner, expect for SGC7901 cells at 24 h (**Figure [1B](#F1){ref-type="fig"}**). Consider reducing the toxicity of drugs to cells and maintaining certain inhibitions against cancer cells, 20 and 30% inhibitory concentration of BBR and MET at 48 h were chosen for the follow-up experiment. The proto-oncogene *C-myc* is closely related to the proliferation of cancer cells. We detected the changes of proliferative gene *C-myc* after treating with BBR and MET by western blotting and RT-PCR. As shown in **Figures [1C,D](#F1){ref-type="fig"}**, BBR (20 and 30 μM) and MET (30 mM) showed the best inhibitory effect on proto-oncogene *C-myc* in AGS cells (*P* \< 0.001). In SGC7901 cells, MET (20 mM) showed a best inhibition (*P* \< 0.001). On the whole, treatment with BBR and MET obviously reduced the protein levels of proliferative gene *C-myc*, compared with untreated AGS and SGC7901 cells. As showed in **Figure [1E](#F1){ref-type="fig"}**, the results showed the same inhibiting trend in mRNA levels after treating with BBR and MET. What's more, the low concentration of BBR and MET had a better effect on inhibiting mRNA expression of proliferative gene *C-myc* than high concentration in both AGS and SGC7901 cells (*P* \< 0.01).

![Effect of Berberine on proliferation in GC cells. Human gastric cancer AGS and SGC7901 cells were treated with BBR and metformin. **(A)** Effect of BBR on cell inhibition at 24, 48, and 72 h. **(B)** Effect of MET on cell inhibition at 24, 48, and 72 h. **(C)** The protein expression of *C-myc* in AGS and SGC7901 cells 48 h after treatment. **(D)** The quantification of *C-myc* protein levels in AGS and SGC7901 cells. **(E)** The quantification of mRNA expression of *C-myc* in AGS and SGC7901 cells 48 h after treatment. Data were presented as the means ± SD. N, untreated cells (normal control group); B20, Berberine (20 μM); B30, Berberine (30 μM); M20, Metformin (20 μM); M30, Metformin (30 μM); *n* = 6 for MTT and *n* = 3 for western-blot and RT-PCR. ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001 vs. normal control group.](fphar-09-01150-g001){#F1}

Berberine Induced G~0~/G~1~ Phase Cell Cycle Arrest
---------------------------------------------------

To investigate how BBR influences cancer cell viability, we stained AGS and SGC7901 with PI and quantified the number of cells in G~0~-G~1~, S, G~2~-M period by flow cytometry. We found that the number of cells in G~0~-G~1~ period increased in both AGS and SGC7901 cells after treating with BBR and MET (*P* \< 0.05, *P* \< 0.01, and *P* \< 0.001) (**Figures [2A,B](#F2){ref-type="fig"}** and **Tables [2](#T2){ref-type="table"}**, **[3](#T3){ref-type="table"}**). Cyclin D1 is a key protein implicated in the transition of the G~0~-G~1~ phase, a decline in Cyclin D1 level indicates a G~0~-G~1~ arrest in cells. We examined both the protein and mRNA levels of Cyclin D1 in AGS and SGC7901 cells separately after the treatment of BBR and MET. The results showed both BBR and MET had negative influence on the protein expression of Cyclin D1 in AGS and SGC7901 cells, and there was a dose-dependent inhibition (*P* \< 0.05 and *P* \< 0.01) (**Figures [2C,D](#F2){ref-type="fig"}**). As shown in **Figure [2E](#F2){ref-type="fig"}**, BBR and MET also downregulated the mRNA level of Cyclin D1 in both AGS and SGC7901 cells, which was consistent with the protein results (*P* \< 0.001).

![Berberine induced G0/G1 phase cell cycle arrest. Human gastric cancer AGS and SGC7901 cells were treated with BBR and MET. At 48 h after treatment, the numbers of cells in G~o~--G~1~, S, and G~2~-M phase were calculated by flow cytometry. **(A)** AGS cells. **(B)** SGC7901 cells. **(C)** The protein expression of Cyclin D1 in AGS and SGC7901 cells 48 h after treatment. **(D)** The quantified western blot of Cyclin D1 in AGS and SGC7901 cells. **(E)** At 48 h after treatment, the quantified mRNA expression of Cyclin D1 in AGS and SGC7901 cells. Data were presented as the means ± SD. *n* = 3 for western-blot and RT-PCR. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001 vs. Normal control group.](fphar-09-01150-g002){#F2}

###### 

Cell cycle ratios of BBR on AGS cell (mean + SD) (%).

  Group                   G0-G1                 S                   G2-M
  ----------------------- --------------------- ------------------- ----------------
  Control                 42.590 + 5.037        40.728 + 4.758      18.170 + 4.341
  Berberine (20 umol/L)   44.145 + 3.856^∗∗∗^   38.118 + 1.223      17.735 + 2.673
  Berberine (30 umol/L)   46.720 + 4.365^∗∗∗^   36.982 + 2.727^∗^   16.302 + 3.071
  Metformin (20 mmol/L)   47.798 + 2.224^∗∗∗^   36.217 + 1.052^∗^   15.972 + 2.156
  Metformin (30 mmol/L)   47.058 + 2.788^∗∗∗^   36.210 + 1.776^∗^   16.733 + 4.457

n = 4 for cell cycle analysis vs. Control,

∗

P \< 0.05 and

∗∗∗

P \< 0.001.

###### 

Cell cycle ratios of BBR on SGC7901 cell (mean + SD) (%).

  Groups                  G0-G1                 S                    G2-M
  ----------------------- --------------------- -------------------- -------------------
  Control                 58.757 + 0.379        25.960 + 1.200       15.283 + 1.424
  Berberine (20 umol/L)   63.533 + 0.973^∗^     24.557 + 1.236       11.913 + 1.415^∗^
  Berberine (30 umol/L)   65.050 + 1.131^∗∗^    22.403 + 1.297^∗^    12.550 + 0.650
  Metformin (20 mmol/L)   69.020 + 1.750^∗∗∗^   21.283 + 2.182^∗^    9.663 + 0.686^∗∗^
  Metformin (30 mmol/L)   69.370 + 4.038^∗∗∗^   18.880 + 2.252^∗∗^   11.753 + 2.449^∗^

n = 3 for cell cycle analysis vs. Control,

∗

P \< 0.05,

∗∗

P \< 0.01, and

∗∗∗

P \< 0.001.

Berberine Inhibited the Migration and Invasion in GC Cells
----------------------------------------------------------

Tumor cell invasion and metastasis are the main characteristics of malignant tumor, which are the leading causes of death in patients with malignant tumor. We used the Transwell assay to examine the effect of BBR and MET on GC cells migratory and invasion. As shown in **Figures [3A--C](#F3){ref-type="fig"}**, the migration numbers of AGS and SGC7901 cells significantly reduced through the Transwell chamber microspores in the treatment group (*P* \< 0.001). When chamber was coated with Matrigel, which was used to mimic the extracellular matrix (ECM) around tumors and to detect the invasion ability of cells. As shown in **Figures [3D--F](#F3){ref-type="fig"}**, The BBR-treated and metformin-treated AGS cells had a significant lower invasion than the untreated cell, the same effect was observed in SGC7901 cells (*P* \< 0.001). With the increase concentration of BBR and MET, the number of gastric cancer cells that invaded and metastasized gradually decreased. Matrix metalloproteinase-3 (MMP-3), known as inducers of EMT, is one of the several MMPs that regulate angiogenesis, invasion and metastasis ([@B19]; [@B8]; [@B36]). It was reported that MMP-3 expression level was negatively correlated with GC development ([@B50]). We used western-blot and RT-PCR to determine whether BBR can affect the expression of matrix metalloproteinase-3 (MMP-3). The results showed that BBR (20 and 30 μM) and MET (30 mM) had stable inhibitory effect on MMP-3 protein expression in AGS and SGC7901 cells (*P* \< 0.01), MET (20 μM) downregulated the expression of MMP-3 in SGC7901 cells, but had no obvious inhibition in AGS cells (**Figures [3G,H](#F3){ref-type="fig"}**). As shown in **Figure [3I](#F3){ref-type="fig"}**, there was a obviously decrease in the mRNA levels of MMP-3 in BBR group compared to untreated group (N) in AGS and SGC7901 cells, MET had similar effect on AGS and SGC7901 cells (*P* \< 0.01 and *P* \< 0.001).

![Berberine inhibited the migration and invasion of GC cells. Human gastric cancer AGS and SGC7901 cells were treated with BBR and MET. Effect of BBR and MET on migration of GC cells after 48 h treatment. Representative images from experiment **(A)** and quantification of migration cell number (**B**: AGS cells; **C**: SGC7901 cells). Effect of BBR and MET on invasion of GC cells after 48 h treatment. Representative images from experiment **(D)** and quantification of invasion cell number (**E**: AGS cells; **F**: SGC7901 cells). Data were presented as the means ± SD, and representative data from at least three independent experiment are shown. **(G)** Protein expression of MMP-3 in AGS and SGC7901 cells 48 h after BBR and MET treatment. **(H)** The quantified western blot of MMP3 in AGS and SGC7901 cells. **(I)** Quantified mRNA expression of MMP3 in AGS and SGC7901 cells 48 h after BBR and MET treatment. *n* = 3 for western-blot and RT-PCR. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗∗^*P* \< 0.0001 vs. Normal control group.](fphar-09-01150-g003){#F3}

Knockdown of HNF4α Attenuated Proliferation, Invasion, and Migration in SGC7901 Cell
------------------------------------------------------------------------------------

Having observed the effect of BBR on gastric cancer, next, we explored the molecular mechanism of BBR against gastric cancer. HNF4α has been reported to be related to malignant tumor formation and metastasis ([@B49]; [@B22]; Maan et al., unpublished). We used lentivirus-mediated transduction of SiRNA-HNF4α to silence the expression of HNF4α in SGC7901 cell, RT-PCR and western blot analyses were performed to confirm target gene knockdown by siRNA. The results showed a 10-fold downregulation of HNF4α expression (**Figures [4A--C](#F4){ref-type="fig"}**).

![Knockdown of HNF4α attenuated proliferation, migration and invasion of SGC7901 cells. Lentivirus-mediated HNF4α siRNA transcript and empty vectors were infected into SGC7901 gastric cancer cells as the Control group and the GFP group respectively. Western-blotting and RT-PCR were used to confirm the knockdown of HNF4α and quantified. **(A)** Representative western-blot images. **(B)** Quantification of Western blot results. **(C)** Quantification of RT-PCR (*n* = 3). We examined the effect of HNF4α knockout on SGC7901 cells. **(D)** Cell proliferation (*n* = 3). **(E)** Cell cycle (*n* = 3). **(F)** Representative images of migration and invasion. **(G)** Quantification of migration and invasion cell number. Data were presented as the means ± SD, with representative data from at least three independent experiments. ^∗∗∗^*P* \< 0.05, ^∗∗∗∗^*P* \< 0.001 vs. Control group. ^\#\#\#^*P* \< 0.001 vs. GFP group.](fphar-09-01150-g004){#F4}

MTT assay was added to detect the proliferation in normal control cells (Control), empty vector control cells (GFP) cells and LV-HNF4α-SGC7901 cells. As shown in **Figure [4D](#F4){ref-type="fig"}**, comparing with the Control and GFP, the knockdown of HNF4α in SGC7901 cells significantly reduced the proliferation (*P* \< 0.0001 and *P* \< 0.001). Also, we stained normal control cells, GFP and LV-HNF4α-SGC7901 cells with PI and quantified the number of cells in G~0~-G~1~, S, G~2~-M period by flow cytometry. As shown in **Figure [4E](#F4){ref-type="fig"}** and **Table [4](#T4){ref-type="table"}**, we found LV-HNF4α-SGC7901 cells increased S population compared with normal control cells and GFP cells (*P* \< 0.05). Moreover, a Transwell assay was used to detect the role of HNF4α in gastric SGC7901 cell migration and invasion. The results showed that knockdown of HNF4α dramatically attenuated the migration and invasion of SGC7901 cell compared with the control cells (*P* \< 0.001 and *P* \< 0.001) (**Figures [4F,G](#F4){ref-type="fig"}**).

###### 

Cell cycle ratios (mean + SD) (%).

  Groups           G~0~-G~1~             S                    G~2~-M
  ---------------- --------------------- -------------------- -------------------
  Normal control   43.68 + 0.383         35.51 + 2.210        20.807 + 1.835
  GFP              48\. 717 + 2.441^∗^   35.760 + 3.080       15.527 + 0.870^∗^
  LV-HNF4α         40.920 + 0.934^∗∗^    40.877 + 1. 160^∗^   18.203 + 0.227

Berberine Regulated HNF4α by Activating AMPK in GC Cells
--------------------------------------------------------

A research has found metformin, a widely used antidiabetic drug, has antitumor activity through modulated HNF4α ([@B6]). Recent study has shown BBR modulates lipid metabolism and inhibits hepatic gluconeogenesis by decreasing expression of HNF4α in type 2 diabetic mouse ([@B47]). Our previous study illustrated BBR prevented fructose-induced insulin resistance by promoting the expression HNF4α in rat livers ([@B48]). In this study, knockdown of HNF4α in SGC7901 cell line slowed its proliferation, induced S phase arrest, dramatically attenuated gastric cancer cells metastasis and invasion and suppressed the tumor growth *in vivo*, the same anti-gastric effect as Berberine. Therefore, we examined how HNF4α was regulated by BBR in GC cell line. BI6015 (an HNF4α antagonist) and AICAR (an AMPK activator) were used and served as positive control.

In AGS cell, BBR and MET significantly decreased the protein level of HNF4α (**Figures [5A,B](#F5){ref-type="fig"}**). BBR (30 μM), MET (30 mM), and AICAR reduced the mRNA expression of HNF4α (**Figure [5D](#F5){ref-type="fig"}**). Although there was no obvious decrease in the protein and mRNA levels of HNF4α after BI6015 treatment (**Figures [5B,D](#F5){ref-type="fig"}**). However, in SGC7901 cell, BI6015 decreased the protein and mRNA expression of HNF4α, the same trend in BBR treatment (**Figures [5C,E](#F5){ref-type="fig"}**). More thrillingly, the protein levels of HNF4α in BBR group were lower than in BI6015 group (*P* \< 0.05). As we expected, MET and AICAR also decreased the protein expression of HNF4α in SGC7901 cells (**Figure [5C](#F5){ref-type="fig"}**).

![Berberine regulated HNF4α by activating AMPK in GC cells. Two GC cell lines, AGS and SGC7901, were treated with BBR (20 μM and 30 μM), metformin (20 mM and 30 mM), BI6015 (an HNF4α antagonist) and AICAR (AMPK agonist). **(A)** The protein expressions of AMPK, p-AMPK and HNF4α in AGS and SGC7901 cells 48 h after treatment. **(B,C)** The quantification of western blot in AGS cells **(B)** and SGC7901 cells **(C)**. **(D,E)** The quantified mRNA expression of AMPK and HNF4α in AGS and SGC7901 cells 48 h after treatment. Two GC cell lines, AGS and SGC7901 cells, were treated with BBR (30 μM) for 24 h, and then with compound C (20 μM) or DMSO for another 24 h. **(F)** The protein expression of AMPK, p-AMPK and HNF4α in AGS and SGC7901 cells after treatment. **(G)** The quantified western blot of AMPK in AGS and SGC7901 cells. **(H)** The quantified western blot of p-AMPK in AGS and SGC7901 cells. **(I)** The quantified western blot of HNF4α in AGS and SGC7901 cells. Data were presented as the means ± SD. *n* = 3 for western-blot and RT-PCR. *T*-test, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001 vs. Normal control group. ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.05 vs. BI6015 group.](fphar-09-01150-g005){#F5}

As for the expression of p-AMPK and AMPK, we used Metformin and AICAR (an AMPK activator) as the positive control, the results showed that BBR (20 μM) increased the protein level of p-AMPK in both AGS and SGC7901 cells (*P* \< 0.05), BBR (30 μM) only upregulated the protein expression of p-AMPK in SGC7901 cell (**Figures [5B,C](#F5){ref-type="fig"}**). Also, we observed that BBR (30 μM) group increased the mRNA level of p-AMPK in both AGS and SGC7901 cells, but not BBR (20 μM) group (**Figures [5D,E](#F5){ref-type="fig"}**). Although no statistically significant differences were found in the total level of AMPK after BBR-treated (**Figures [5A--E](#F5){ref-type="fig"}**).

To explore the interaction between AMPK and HNF4α in gastric cells, we used BBR and Compound C (AMPK inhibitor) to treat two GC cell lines and detected the changes in the protein levels of HNF4α. The results showed, BBR treatment increased p-AMPK expression and decreased HNF4α expression in GC cells, Compound C decreased p-AMPK expression and increased HNF4α expression in GC cells, there was a negative relationship between AMPK and HNF4α in GC cells (**Figures [5F,H,I](#F5){ref-type="fig"}**). Compound C weakened the inhibition of HNF4α by BBR, suggesting that HNF4α may be the downstream of AMPK in GC cells. Both BBR and Compound C had no effect on the total AMPK protein level (**Figure [5G](#F5){ref-type="fig"}**).

Berberine Targeted the WNT/β-Catenin Signaling Through Regulating HNF4α in GC Cells
-----------------------------------------------------------------------------------

WNT signaling plays an important role in gastric cancer development, especially WNT5A, a member of the WNT family of secreted lipid-modified glycoproteins, was closely related to the gastric cancer invasion and metastasis ([@B21]; [@B3]). Recent research has found that WNT5A is a direct target gene of HNF4α in GC ([@B33]). To explore how BBR exerts anti-tumor effect by HNF4α acting on downstream targets, Western blot and Real Time PCR were performed to detect the mRNA and protein levels of WNT signaling after BBR-treated. We used BBR, metformin, AICAR (AMPK activator) and BI6015 (an HNF4α antagonist) to interfere with two GC cells. As shown in **Figures [6A--E](#F6){ref-type="fig"}**, BBR and MET (20 mM) decreased the protein and mRNA expression of WNT5A and cytoplasmic β-catenin in both AGS and SGC7901 cells. MET (30 mM) produced the same inhibitory effect in modulating the WNT signaling pathway as MET (20 mM) in GC cells expect the protein expression of WNT5A in AGS cell. To further investigate the downstream of HNF4α in GC cells, we used SiRNA- HNF4α SGC7901 cell model to detect the WNT pathway. Western blot and Real Time PCR separately were used to test the mRNA and protein levels of WNT5A, cytoplasmic β-catenin, E-cadherin and CyclinD1. The WNT/β-catenin, being the canonical WNT pathway, which can induce the expression of CyclinD1 ([@B25]). E-cadherin, another member of WNT pathway, is lost in some cancers, allowing cellular migration to the stroma ([@B23]). As shown in **Figures [6F,G](#F6){ref-type="fig"}**, comparing with normal control cells and Lenti-GFP cells, the protein expression of WNT5A, cytoplasmic β-catenin, and Cyclin D1 decreased while the expression of E-cadherin increased in LV-HNF4α-SGC7901 cell. In mRNA level, there were obvious low levels of WNT5A, cytoplasmic β-catenin, and Cyclin D1 in LV-HNF4α-SGC7901 cell, and the level of E-cadherin in LV-HNF4α-SGC7901 cells was higher in normal control cells and Lenti-GFP cells (**Figure [6H](#F6){ref-type="fig"}**).

![Berberine targeted WNT/β -catenin signaling through HNF4α in GC cells. First, two GC cell lines, AGS and SGC7901, were treated with BBR (20 μM and 30 μM), metformin (20 mM and 30 mM), BI6015 (an HNF4α antagonist) and AICAR (AMPK agonist). **(A)** The protein expression of WNT5A and cytoplasmic β-catenin in AGS and SGC7901 cells 48 h after treatment. **(B,C)** The quantified western blot of WNT5A and cytoplasmic β-catenin in AGS and SGC7901 cells. **(D,E)** The quantified mRNA expression of WNT5A and cytoplasmic β-catenin in AGS and SGC7901 cells 48 h after treatment. Next, an siRNA-HNF4α SGC7901 cell model was used to detect the WNT pathway. **(F)** The protein level of WNT5A, cytoplasmic β-catenin, E-cadherin and Cyclin D1 in Control, GFP and LV-HNF4α SGC7901 cell lines. **(G)** The quantified western blot of WNT5A, cytoplasmic β-catenin, E-cadherin and Cyclin D1. **(H)** The quantified mRNA level of WNT5A, cytoplasmic β-catenin, E-cadherin and Cyclin D1 in Control, GFP and LV-HNF4α SGC7901 cell lines. Data were presented as the means ± SD. *n* = 3 for western-blot and RT-PCR. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001 vs. Control group.](fphar-09-01150-g006){#F6}

Knockdown of HNF4α Suppressed Xenograft Tumor Growth *in vivo*
--------------------------------------------------------------

BALB/c nude mouse models with xenografted human SGC7901 cells, Lenti-GFP and LV-HNF4α-SGC7901 cells were employed to evaluate the effect of HNF4α on tumor growth *in vivo*. Eighteen days after inoculation, the body weight remained consistent between these groups (**Figure [7A](#F7){ref-type="fig"}**). the average final tumor weight and volume in the LV-HNF4α group were 0.01 g and 6.268 mm^3^, respectively, which was significantly lower than those in normal control group (0.253 g, 234.0571 mm^3^) and Lenti-GFP group (0.133 g, 71.928 mm^3^) (*P* \< 0.05) (**Figures [7B--D](#F7){ref-type="fig"}**). There was no statistical difference in tumor weight and volume between normal control group and Lenti-GFP group. Those results suggested that knockdown of HNF4α suppressed gastric cancer tumor growth *in vivo*.

![Effect of HNF4α on SGC7901 xenograft tumor growth *in vivo*. The normal control, Lenti-GFP, and LV-HNF4α SGC7901 cells were injected subcutaneously into the right scapular region of nude mice. **(A)** Body weight. **(B)** The average tumor volume is shown as the mean ± SD (mm^3^). **(C)** Tumor weight. **(D)** The tumors removed from mice are shown. **(E)** Representative images from immunohistochemical staining of HNF4α, WNT5A and β-catenin in tumors from each group (50x Lenti). **(F--H)** The quantified immunohistochemistry of HNF4α, WNT5A and β-catenin. Data were expressed as the means ± SD. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001 vs. normal control group.](fphar-09-01150-g007){#F7}

We used immunohistochemistry to exam the HNF4α, WNT5A and cytoplasmic β-catenin expression in gastric cancer tumors of mice. The results showed that the expression of HNF4α decreased in LV-HNF4α group, but did not decrease in normal control group and Lenti-GFP group. The WNT5A and cytoplasmic β-catenin expression were decreased in LV- HNF4α group, which was consistent with previous cell experiments (**Figures [7E--H](#F7){ref-type="fig"}**) (*P* \< 0.0001).

Berberine Suppressed Xenograft Tumor Growth *in vivo*
-----------------------------------------------------

The SGC7901 cells were injected subcutaneously into BALB/c nude mouse, normal saline, Berberine and metformin were treated, respectively. During the 18 days treatment, the weight of each group was not statistically significant (**Figure [8A](#F8){ref-type="fig"}**). As shown in **Figures [8B--D](#F8){ref-type="fig"}**, 250 mg/kg MET (SGC-M) significantly suppressed the tumor growth *in vivo* compared with normal control group (SGC-N). The average final tumor weight and volume in the SGC-M group were 0.023 g and 68.168 mm^3^, respectively, which was significantly lower than those in SGC-N group (0.297 g, 278.213 mm^3^) (*P* \< 0.001 and *P* \< 0.01). There was also a reduction in tumor weight and volume in the BBR (100 mg/kg) group (SGC-B) compared with normal control group, the average final tumor weight and volume were 0.143 g and 163.955 mm^3^ (*P* \< 0.01 and *P* \< 0.05).

![Effect of BBR on SGC7901 xenograft tumor growth *in vivo*. The SGC7901 cells were injected subcutaneously into the right scapular region of nude mice, and were given normal saline, Berberine or metformin treatment. **(A)** Body weight. **(B)** The average tumor volume is shown as the means ± SD (mm^3^). **(C)** Tumor weight. **(D)** The tumors removed from mice are shown. **(E)** Representative images from immunohistochemical staining of HNF4α, WNT5A and β-catenin in tumors from each group (50× magnification). **(F--H)** The quantified immunohistochemistry of HNF4α, WNT5A and β-catenin. Data were expressed as the means ± SD. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001 vs. normal group.](fphar-09-01150-g008){#F8}

To further investigate the insight mechanism of BBR on gastric cancer tumor *in vivo*, immunohistochemistry was used to detect the HNF4α, WNT5A and cytoplasmic β-catenin expression in xenografted tumors. As shown in **Figures [8E--H](#F8){ref-type="fig"}**, the BBR (100 mg/kg) and MET (250 mg/kg) decreased the HNF4α, WNT5A and cytoplasmic β-catenin expression comparing with the normal control group (*P* \< 0.0001). There was no difference between BBR group and MET group in HNF4α, WNT5A and cytoplasmic β-catenin expression.

Discussion
==========

Berberine (BBR), an isoquinoline alkaloid isolated from Berberis vulgaris, used to be an antibacterial agent in China for a long time. Over the past decade, It has been reported that BBR could also regulate plasma lipid and glucose levels in type 2 diabetes animal models and humans ([@B24]; [@B34]; [@B38]; [@B43]). Our previous studies have indicated that BBR can stimulate insulin secretion and modulate lipids in impaired glucose tolerance rats ([@B27]), reverse free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes ([@B55]), even attenuate intestinal mucosal barrier dysfunction and immune barrier damages in type 2 diabetic rats ([@B16]). In this study, we found that BBR had proliferation inhibition effect on AGS and SGC7901 gastric cancer cell lines in a time and dose-dependent manner. We also detected the proto-oncogene expression of *C-myc*, which frequently upregulates in human cancers and accelerates cell proliferation ([@B10]). The results showed that BBR downregulated the mRNA and protein expression of *C-myc* in both GC cell lines, suggesting BBR has potential anti-gastric cancer effect as previous researches have shown ([@B56]; [@B28]; [@B53]).

The balance between cell cycle and cell proliferation often deregulated in cancers ([@B15]). Then, we detected the effects of BBR on GC cell cycle. After BBR treatment, the number of cells in G~0~-G~1~ period increased, and the protein and mRNA expression of CyclinD1 decreased significantly in both AGS and SGC7901 cells. Cyclin D1 is a key protein implicated in the transition of the G~0~-G~1~ phase, which allows cells to enter the G~1~ phase of the cell cycle and promotes cell proliferation ([@B15]; [@B45]). The decreased expression of Cyclin D1 indicates a G~0~-G~1~ arrest in cells. So the flow cytometry, western blot and RT-PCR results all showed that BBR induced G~0~-G~1~ phase arrest in AGS and SGC7901 gastric cancer cell lines.

The depth of tumor invasion and lymph node metastasis are considered as the most important prognostic predictors of gastric cancer ([@B13]). It is essential to explore the mechanisms of invasion and metastasis to improve the survival rate for cancer patients ([@B58]). We used the Transwell assay to examine whether BBR affected GC cells' migration and invasion or not. With the increased dose of BBR, the number of gastric cancer cells that invaded and metastasized dramatically decreased. MMP-3, known as inducers of EMT, is one of the several MMPs that regulate angiogenesis, invasion and metastasis ([@B19]; [@B8]; [@B36]).It was reported that MMP-3 expression level was negatively correlated with GC development ([@B50]). We also found that BBR had stable inhibitory effect on matrix metalloproteinase-3 (MMP-3) protein and mRNA expressions in AGS and SGC7901 cells, which suggested that BBR inhibited the migration and invasion to prevent GC development through downregulating MMP-3 in AGS and SGC7901 GC cells.

Previous researches reported that Metformin (MET) inhibited gastric cancer cells metastatic traits and slowed gastric tumor growth ([@B9]; [@B41]). In the present study, we also found that BBR, a widely used antibacterial drug, had multiple anti-tumor efficacy on AGS and SGC7901 GC cell lines as MET. We know BBR shares many features in metabolism regulation with MET. Recent researches have demonstrated that MET acted directly on cancer cells by targeting tumor metabolism, and inhibited the migration and invasion of the esophageal carcinoma cell line EC109 ([@B12]; [@B18]). Among patients with T2DM, some clinical evidences have shown those who took metformin therapy have a lower risk of GC than those who didn't ([@B57]; [@B29]). Moreover, it was reported that the anti-gastric cancer effect of metformin was related with the HNF4α inhibition through AMPK signaling ([@B6]). AMPK directly or indirectly inhibits HNF4α and its downstream HIF-1α, which is consistent with a proposed role for AMPK in suppressing the 'Warburg effect' anaerobic metabolism characteristic of the malignant phenotype ([@B22]).

Hepatocyte nuclear factor 4α is a nuclear receptor that activates the expression of genes involved in endoderm development and glucose, fatty acid and cholesterol metabolism ([@B11]). Previous studies suggested HNF4α is a potential direct or indirect target for pharmacological drugs that act on the intestinal epithelium, which is a primary site of metabolic control ([@B5]). Recent studies have found that HNF4α is related to malignant tumor formation and metastasis ([@B49]; [@B22]; Maan et al., unpublished). It was significantly upregulated in multidrug-resistant GC cells ([@B31]). To assess the function of HNF4α in GC cells, we used siRNA to silence the expression of HNF4α and tested the proliferation, cell cycles, migration and invasion in SGC7901 cell. We found that knockdown of HNF4α in SGC7901 cell line slowed its proliferation, induced S phase arrest and dramatically attenuated gastric cancer cells' metastasis and invasion. It demonstrated that HNF4α was involved in the growth, invasion and metastasis capacity of gastric cancer. HNF4α gene could serve as a "proto-oncogene" in gastric cancer development.

Our previous studies have indicated that BBR modulates lipid metabolism and inhibits hepatic gluconeogenesis by targeting HNF4α in type 2 diabetic rats ([@B14]; [@B46]; [@B52]). Is the anti-gastric cancer effect of Berberine related with tumor metabolism? How is HNF4α regulated by BBR in GC cell line? We performed GC cell perturbation experiments through BI6015 (an HNF4α antagonist), AICAR (an AMPK activator), metformin, and Berberine. The results showed that BBR downregulated the expression of HNF4α in two GC cells. Given that AMPK mediated the phosphorylation of HNF4α, and prevented transcription factor HNF4α from entering the nucleus to form dimer and DNA binding to improve the degradation of HNF4α ([@B26]). We also observed that BBR (20 μM) upregulated the protein level of phosphor-AMPK (p-AMPK) and BBR (30 μM) upregulated the mRNA level of total AMPK in GC cells,MET increased the mRNA expression of AMPK in GC cells, although no statistically significant differences were found in the total protein level of AMPK after BBR and MET treatment. To further confirm the AMPK may be the potential upstream of HNF4α in GC cells, we used Compound C (AMPK-kinase inhibitor) and BBR to treat two GC cells. We found that BBR downregulated the protein level of HNF4α and Compound C upregulated the expression of HNF4α, Compound C reversed the effect of BBR on the HNF4α, suggesting inhibition of HNF4α by BBR was AMPK dependent. There was a negative correlation between p-AMPK and HNF4α. That means, BBR upregulated the protein of p-AMPK and Compound C downregulated the expression. This phenomenon indicated that HNF4α may be the downstream of AMPK and BBR could regulate the AMPK/HNF4α pathway in gastric cancer cells.

WNT/β-catenin signaling is important for cancer progression, including tumor initiation, tumor growth, cell senescence, cell death, differentiation and metastasis ([@B2]). It was also reported that HNF4α-WNT5A regulation was the cross-talk between the AMPK metabolic pathway and the WNT signaling pathway ([@B33]). WNT5A, a member of the WNT family, played an important role in gastric cancer invasion and metastasis ([@B21]; [@B3]). Knockdown of WNT5A reduced the metastasis ability of gastric cancer cells ([@B17]). Then, we explored how BBR acted on WNT/β-catenin signaling pathway in GC cell lines. Our study demonstrated that BBR downregulated the protein and mRNA levels of WNT5A and cytoplasmic β-catenin in AGS and SGC7901 cell lines. To further identify the relationship between HNF4α and WNT signal pathway. SiRNA- HNF4α SGC7901 cell model was used to detect the expression of WNT pathway. The results showed that knockdown of HNF4α decreased significantly the protein and mRNA expression levels of WNT5A, cytoplasmic β-catenin and cyclinD1 *in vitro*, and increased significantly the expression of E-cadherin comparing with control cells. HNF4α was reported to compete with β-catenin for binding to TCF4, regulating Epithelial-to-mesenchymal transition (EMT) ([@B54]). Loss of E-cadherin is regarded as a major conventional marker of the EMT ([@B1]; [@B51]). Our study validated that WNT5A was a downstream target gene of HNF4α and showed that knockdown of HNF4α decreased the expression of WNT5A and cytoplasmic β-catenin in GC cell line, which is consistent with the study of [@B6]. But studies have illustrated, in small intestine and colon cancer, loss of HNF4α activated the WNT/β-catenin signaling pathway. In these cancer tissues, HNF4α was low expressed compared with adjacent normal tissues ([@B5]; [@B54]).

Meanwhile, we analyzed that effect of BBR and HNF4α on gastric cancer tumor *in vivo*. Our results showed that BBR and knockdown of HNF4α suppressed the growth of SGC7901 in nude mice, HNF4α played a critical role in gastric cancer development and might serve as a potential therapy biomarker. Consistent with *in vitro* experiments, BBR downregulated HNF4α, WNT5A, and cytoplasmic β-catenin expression in somatic tumor tissues, the same effect as knocking out HNF4α gene.

Taken together, in the present study, we demonstrated that BBR, an anti-diabetes herb monomer, not only had proliferation inhibition effect on GC cell lines through downregulating cell cycle protein CyclinD1, attenuated the invasion and migration of GC cells by decreasing MMP-3, but also suppressed the growth of gastric tumor. The anti-gastric cancer mechanism of BBR might be involved in AMPK-HNF4α-WNT5A signaling pathway. BBR could modulate HNF4α through AMPK signaling. Moreover, HNF4α could regulate WNT-β-catenin-E-cadherin signaling to attenuate the growth, invasion and metastasis of gastric cancer. Therefore, HNF4α, a nuclear receptor that activated the expression of genes involved in glucose, fatty acid and cholesterol metabolism, was also involved in the development of gastric cancer. HNF4α antagonists, such as BBR, could be a promising anti-gastric cancer treatment supplement.
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